NcXHF

GRÜNHAGEN, KROON, AND VERHOEF
26. Kroon HM, Thompson JF. Isolated limb infusion: a review. J Surg Oncol.
2009;100:169-177.
27. Wu ZY, Smithers BM, Parsons PG, et al. The effects of perfusion conditions
on melphalan distribution in the isolated perfused rat hindlimb
bearing a human melanoma xenograft. Br J Cancer. 1997;75:1160-1166.
28. Wu ZY, Smithers BM, Roberts MS. Tissue and perfusate pharmacokinetics
of melphalan in isolated perfused rat hindlimb. J Pharmacol Exp
Ther. 1997;282:1131-1138.
29. Kroon HM, Huismans A, Waugh RC, et al. Isolated limb infusion: technical
aspects. J Surg Oncol. 2014;109:352-356.
30. Klaase JM, Kroon BB, Benckhuijsen C, et al. Results of regional isolation
perfusion with cytostatics in patients with soft tissue tumors of the extremities.
Cancer. 1989;64:616-621.
31. Deroose JP, Grünhagen DJ, de Wilt JH, et al. Treatment modifıcations
in tumour necrosis factor- (TNF)-based isolated limb perfusion in patients
with advanced extremity soft tissue sarcomas. Eur J Cancer. 2015;
51:367-373.
32. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter
trial of hyperthermic isolated limb perfusion with melphalan alone
compared with melphalan plus tumor necrosis factor: American College
of Surgeons Oncology Group Trial Z0020. J Clin Oncol. 2006;24:
4196-4201.
33. Noorda EM, Vrouenraets BC, Nieweg OE, et al. Isolated limb perfusion
for unresectable melanoma of the extremities. Arch Surg. 2004;139:
1237-1242.
34. Alexander HR Jr, Fraker DL, Bartlett DL, et al. Analysis of factors influencing
outcome in patients with in-transit malignant melanoma undergoing
isolated limb perfusion using modern treatment parameters.
J Clin Oncol. 2010;28:114-118.
35. Hoekstra HJ, Veerman K, van Ginkel RJ. Isolated limb perfusion for
in-transit melanoma metastases: melphalan or TNF-melphalan perfusion?
J Surg Oncol. 2014;109:338-347.
36. Rossi CR, Pasquali S, Mocellin S, et al. Long-term results of melphalanbased
isolated limb perfusion with or without low-dose TNF for intransit
melanoma metastases. Ann Surg Oncol. 2010;17:3000-3007.
37. Di Filippo F, Giacomini P, Rossi CR, et al. Prognostic factors influencing
tumor response, locoregional control and survival, in melanoma patients
with multiple limb in-transit metastases treated with TNFalphabased
isolated limb perfusion. In Vivo. 2009;23:347-352.
38. Deroose JP, Eggermont AM, van Geel AN, et al. 20 years experience of
TNF-based isolated limb perfusion for in-transit melanoma metastases:
TNF dose matters. Ann Surg Oncol. 2012;19:627-635.
39. Olofsson R, Mattsson J, Lindner P. Long-term follow-up of 163 consecutive
patients treated with isolated limb perfusion for in-transit metastases
of malignant melanoma. Int J Hyperthermia. 2013;29:551-557.
40. Deroose JP, Eggermont AM, van Geel AN, et al. Isolated limb perfusion for
melanoma in-transit metastases: developments in recent years and the role
of tumor necrosis factor alpha. Curr Opin Oncol. 2011;23:183-188.
41. Kroon HM, Moncrieff M, Kam PC, et al. Outcomes following isolated
limb infusion for melanoma. A 14-year experience. Ann Surg Oncol.
2008;15:3003-3013.
42. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience
of isolated limb infusion: defıning response and toxicity in the US.
J Am Coll Surg. 2009;208:706-715; discussion 715-717.
43. Coventry BJ, Kroon HM, Giles MH, et al. Australian multi-center experience
outside of the Sydney Melanoma Unit of isolated limb infusion
chemotherapy for melanoma. J Surg Oncol. 2014;109:780-785.
44. Kroon HM, Huismans AM, Kam PC, et al. Isolated limb infusion with
melphalan and actinomycin D for melanoma: a systematic review. J Surg
Oncol. 2014;109:348-351.
45. Wong J, Chen YA, Fisher KJ, et al. Resection of residual disease after
isolated limb infusion (ILI) is equivalent to a complete response after
ILI-alone in advanced extremity melanoma. Ann Surg Oncol. 2014;21:
650-655.
46. Grünhagen DJ, van Etten B, Brunstein F, et al. Effıcacy of repeat isolated
limb perfusions with tumor necrosis factor alpha and melphalan for
multiple in-transit metastases in patients with prior isolated limb perfusion
failure. Ann Surg Oncol. 2005;12:609-615.
47. Kroon HM, Lin DY, Kam PC, et al. Effıcacy of repeat isolated limb infusion
with melphalan and actinomycin D for recurrent melanoma.
Cancer. 2009;115:1932-1940.
48. Kroon HM, Lin DY, Kam PC, et al. Safety and effıcacy of isolated limb
infusion with cytotoxic drugs in elderly patients with advanced locoregional
melanoma. Ann Surg. 2009;249:1008-1013.
49. Wieberdink J, Benckhuysen C, Braat RP, et al. Dosimetry in isolation
perfusion of the limbs by assessment of perfused tissue volume and
grading of toxic tissue reactions. Eur J Cancer Clin Oncol. 1982;18:905-
910.
50. Bonvalot S, Laplanche A, Lejeune F, et al. Limb salvage with isolated
perfusion for soft tissue sarcoma: could less TNF-alpha be better? Ann
Oncol. 2005;16:1061-1068.
51. Kroon HM, Moncrieff M, Kam PC, et al. Factors predictive of acute
regional toxicity after isolated limb infusion with melphalan and actinomycin
D in melanoma patients. Ann Surg Oncol. 2009;16:1184-1192.
52. Egger ME, Brown RE, Roach BA, et al. Addition of an iliac/obturator
lymph node dissection does not improve nodal recurrence or survival in
melanoma. J Am Coll Surg. 2014;219:101-108.
53. Mann GB, Coit DG. Does the extent of operation influence the prognosis
in patients with melanoma metastatic to inguinal nodes? Ann Surg
Oncol. 1999;6:263-271.
54. Menzies AM, Long GV. Systemic treatment for BRAF-mutant melanoma:
where do we go next? Lancet Oncol. 2014;15:e371-e381.
55. Grünhagen DJ, Brunstein F, Graveland WJ, et al. One hundred consecutive
isolated limb perfusions with TNF-alpha and melphalan in melanoma
patients with multiple in-transit metastases. Ann Surg. 2004;240:
939-948.
56. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in
melanoma with combined dabrafenib and trametinib. N Engl J Med.
2015;372:30-39.
57. Beasley GM, Coleman AP, Raymond A, et al. A phase I multiinstitutional
study of systemic sorafenib in conjunction with regional
melphalan for in-transit melanoma of the extremity. Ann Surg Oncol.
2012;19:3896-3905.
58. Beasley GM, Riboh JC, Augustine CK, et al. Prospective multicenter
phase II trial of systemic ADH-1 in combination with melphalan via
isolated limb infusion in patients with advanced extremity melanoma.
J Clin Oncol. 2011;29:1210-1215.
59. Turley RS, Fontanella AN, Padussis JC, et al. Bevacizumab-induced alterations
in vascular permeability and drug delivery: a novel approach to
augment regional chemotherapy for in-transit melanoma. Clin Cancer
Res. 2012;18:3328-3339.
60. Klaase JM, Kroon BB, van Geel AN, et al. Limb recurrence-free interval
and survival in patients with recurrent melanoma of the extremities
treated with normothermic isolated perfusion. J Am Coll Surg. 1994;178:
564-572.
61. Lingam MK, Byrne DS, Aitchison T, et al. A single centre’s 10 year experience
with isolated limb perfusion in the treatment of recurrent malignant
melanoma of the limb. Eur J Cancer. 1996;32A:1668-1673.
62. Aloia TA, Grubbs E, Onaitis M, et al. Predictors of outcome after hyperthermic
isolated limb perfusion: role of tumor response. Arch Surg.
2005;140:1115-1120.
63. Wong J, Chen YA, Fisher KJ, et al. Isolated limb infusion in a series of
over 100 infusions: a single-center experience. Ann Surg Oncol. 2013;20:
1121-1127.
e534
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook